NextCure, Inc. (NXTC)
- Simply Wall St.
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment completedCash of approximately $86.4 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a busi
- GlobeNewswire
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024. A recording of the webcast will be available on the conference day starting at 7 AM ET through the Investo
